New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes
|
Jun 2017
|
Am Soc Clin Oncol Educ Book
|
myelodysplastic syndromes (MDS)
|
Standardized High-Sensitivity Flow Cytometry Testing for Paroxysmal Nocturnal Hemoglobinuria in Children with Acquired Bone Marrow Failure Disorders: A Single Center U.S. Study
|
Jun 2017
|
Cytometry B Clin Cytom
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents
|
Jun 2017
|
Biol Blood Marrow Transplant
|
myelodysplastic syndromes (MDS)
|
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.
|
Jun 2017
|
Oncotarget
|
myelodysplastic syndromes (MDS)
|
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy
|
Jun 2017
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
|
Jun 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways
|
Jun 2017
|
J Immunol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
|
Jun 2017
|
Semin Hematol
|
|
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity
|
Jun 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
First-line Therapeutic Strategies for Myelodysplastic Syndromes.
|
Jul 2017
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|